Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 77,605	$ 24,194
Marketable securities	0	27,802
Prepaid expenses and other assets	2,866	2,596
Total current assets	80,471	54,592
Property and equipment, net	6,764	8,628
Right of use assets – operating leases	2,173	4,822
Deferred financing costs	146	4,111
Total assets	89,554	72,153
Current liabilities:
Accounts payable	3,933	1,728
Accrued expenses	7,662	10,361
Deferred revenue	1,413	2,459
Operating lease liabilities	1,391	3,437
Finance lease liabilities	544	1,162
Other current liabilities	965	523
Total current liabilities	15,908	19,670
Deferred revenue	45,000	45,000
Convertible promissory note	0	33,717
Derivative liability	0	5,739
Operating lease liabilities	860	976
Finance lease liabilities	328	872
Other long-term liabilities	926	1,041
Total liabilities	63,022	107,015
Commitments and contingencies (Note 7)
Convertible preferred stock	0	107,808
Stockholders’ equity (deficit):
Preferred stock $0.001 par value, 5,000,000 shares authorized, none issued or outstanding	0	0
Common stock $0.001 par value, 350,000,000 shares authorized, 40,609,915 and 2,217,737 shares issued and outstanding at December 31, 2023 and 2022, respectively	40	2
Additional paid-in capital	271,594	1,197
Accumulated other comprehensive loss	0	(41)
Accumulated deficit	(245,102)	(158,223)
Total Carisma Therapeutics Inc. stockholders’ equity (deficit)	26,532	(157,065)
Noncontrolling interests	0	14,395
Total stockholders’ equity (deficit)	26,532	(142,670)
Total liabilities, convertible preferred stock and stockholders’ equity (deficit)	$ 89,554	$ 72,153